Advertisement

Topics

CHMP Backs First-in-Class Drug Emicizumab for Hemophilia A

13:55 EST 26 Jan 2018 | Medscape

The CHMP recommended marketing authorization for emicizumab. a first-in-class drug for patients of all ages with hemophilia A with factor VIII inhibitors.
International Approvals

Original Article: CHMP Backs First-in-Class Drug Emicizumab for Hemophilia A

NEXT ARTICLE

More From BioPortfolio on "CHMP Backs First-in-Class Drug Emicizumab for Hemophilia A"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...